Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378995 | 0.96 | MAPT (0.39) | LMNACA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL27845584 | 0.84 | MAPT (0.40) | LMNACA12CA1CA2CA3 | |
| SCHEMBL692238 | 0.78 | ALDH1A1 (0.36) | LMNACA12CA1CA2CA3 | |
| SCHEMBL692169 | 0.77 | MAPT (0.47) | LMNAMAPTSMN1; SMN2TP53POLB | |
| SCHEMBL692261 | 0.76 | BRD4 (0.46) | — | |
| SCHEMBL8349122 | 0.76 | ALPL (0.37) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8276503 | 0.76 | FAAH (0.42) | LMNAMAPTSMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL29591789 | 0.74 | MAPT (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL6833044 | 0.73 | PTPN1 (0.36) | MAPTSMN1; SMN2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL12975343 | 0.73 | BRD4 (0.38) | ALDH1A1HSD17B10TDP1ALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1997363-B | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS | 2012-03-28 | — | — | CN | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | LMNA 4196/4885CA12 4388/4885CA1 3305/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | LMNA 4196/4885CA12 4388/4885CA1 3305/4885 |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SERPINB1, MMP7, MME | LMNA 4196/4885CA12 4388/4885CA1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.